四学会联合声明:分化型甲状腺癌131I治疗争议与共识
美国甲状腺协会、欧洲核医学协会、核医学与分子影像学会及欧洲甲状腺协会联合召开会议,针对分化型甲状腺癌131I治疗的分歧进行讨论,形成九项马丁尼克原则,强调跨学科合作、明确治疗目标、综合评估术后状态,并指出辅助治疗最佳剂量及难治性定义尚不明确。
要点
- 131I治疗目标应明确为残留消融、辅助治疗或已知病灶治疗。
- 决策需结合术后疾病状态及临床病理分期外的多种因素。
- 辅助治疗最佳剂量无法从现有文献确定,难治性定义不完善。
核心结论
- 四学会通过建设性对话达成九项马丁尼克原则,以促进分化型甲状腺癌131I治疗的合理应用。
研究设计与样本
- 四学会各派高级领导和专家参加为期两天的互动会议,形成联合声明。
主要发现
- 会议明确了131I治疗的三个目标:残留消融、辅助治疗和治疗已知疾病。
- 强调术后疾病状态评估及临床病理分期外多因素对决策的重要性。
- 指出辅助治疗最佳给药活度无法从已发表文献确定。
- 认为当前131I难治性疾病的定义欠佳,不能作为强制推荐治疗的明确标准。
关键数值与推荐
- 九项原则包括:承诺主动、有目的和包容的跨学科合作;定义131I治疗目标;强调评估术后疾病状态;承认辅助治疗最佳活度不确定;承认难治性定义不完善。
临床怎么用
- 临床决策应基于术后疾病状态和综合因素,而非仅依赖分期。
- 与患者沟通时需明确131I治疗的具体目标(消融、辅助或治疗)。
- 对辅助治疗剂量和难治性判定应保持谨慎,结合多学科讨论。
局限性
- 会议未提供具体剂量推荐或难治性判定标准,相关争议仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Publication of the 2015 American Thyroid Association (ATA) management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer was met with disagreement by the extended nuclear medicine community with regard to some of the recommendations related to the diagnostic and therapeutic use of radioiodine (131I). Because of these concerns, the European Association of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging declined to endorse the ATA guidelines. As a result of these differences in opinion, patients and clinicians risk receiving conflicting advice with regard to several key thyroid cancer management issues. SUMMARY: To address some of the differences in opinion and controversies associated with the therapeutic uses of 131I in differentiated thyroid cancer constructively, the ATA, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association each sent senior leadership and subject-matter experts to a two-day interactive meeting. The goals of this first meeting were to (i) formalize the dialogue and activities between the four societies; (ii) discuss indications for 131I adjuvant treatment; (iii) define the optimal prescribed activity of 131I for adjuvant treatment; and (iv) clarify the definition and classification of 131I-refractory thyroid cancer. CONCLUSION: By fostering an open, productive, and evidence-based discussion, the Martinique meeting restored trust, confidence, and a sense of collegiality between individuals and organizations that are committed to optimal thyroid disease management. The result of this first meeting is a set of nine principles (The Martinique Principles) that (i) describe a commitment to proactive, purposeful, and inclusive interdisciplinary cooperation; (ii) define the goals of 131I therapy as remnant ablation, adjuvant treatment, or treatment of known disease; (iii) describe the importance of evaluating postoperative disease status and multiple other factors beyond clinicopathologic staging in 131I therapy decision making; (iv) recognize that the optimal administered activity of 131I adjuvant treatment cannot be definitely determined from the published literature; and (v) acknowledge that current definitions of 131I-refractory disease are suboptimal and do not represent definitive criteria to mandate whether 131I therapy should be recommended.
引用
- Tuttle RM, Ahuja S, Avram AM, et al. Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019. PMID: 30900516. doi:10.1089/thy.2018.0597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。